Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.